CFN Media Group ("CannabisFN"), the leading creative agency and
media network dedicated to legal cannabis, announces publication of
an article covering India Globalization Capital
Inc.’s (NYSE: American: IGC) partnership strategies that place
the company in the forefront of cannabinoid-based Parkinson’s
disease research.
India Globalization Capital is focused on
developing cannabis-based therapeutics targeting a wide range of
disease, including Parkinson’s disease. After partnering with a
leading Parkinson’s disease institute, the company hopes to design
clinical trials that could prove the efficacy of medical cannabis
and help physicians prescribe the plant.
Parkinson’s disease affects about one million
Americans and ten million individuals around the world, costing the
economy more than $25 billion per year. While there is no cure for
the disease, there are many different ways to manage symptoms.
Medical marijuana has been one of the most common self-treatment
options for those suffering from the disease, but physicians are
waiting for more clinical data before recommending the medicine to
patients.
Parkinson’s Disease Market
Parkinson’s disease affects about one million
Americans and ten million individuals around the world, which is
more than the combined number of people with multiple sclerosis,
muscular dystrophy, and Lou Gehrig’s disease. Approximately 60,000
Americans are newly diagnosed with Parkinson’s disease each year
and those figures are set to increase as the U.S. population ages,
since the disease incidence increases with age.
The direct and indirect costs of Parkinson’s
disease is estimated to be nearly $25 billion per year in the
United States alone. These costs include treatment, social security
payments, and lost income. Medications cost an average of $2,500
per year and therapeutic surgery can cost upwards of $100,000 per
person.
While there are several potential protective
factors, including caffeine consumption, anti-inflammatory drug
intake, and exercise, there are no cures for Parkinson’s disease.
Most treatments start with levodopa preparations or agonists, like
an MAO inhibitor or an anticholinergic. Surgery options, like deep
brain stimulation, can also help improve symptoms in patients that
have responded to levodopa.
Medical cannabis has shown promise as a treatment
for Parkinson’s disease. In fact, a study by the Parkinson’s
Foundation found that 80 percent of patients have used the
plant. Physicians surveyed in the study struggled to recommend
cannabis given the lack of clinical data, but indicated that they
would be more apt to use medical marijuana as a treatment if it
were approved through regulation instead of legislation.
New Partnership Agreement
India Globalization Capital is developing
cannabis-based compounds that could become part of the solution to
treat the symptoms of progressive diseases like Parkinson’s
disease. Its Serosapse program addresses several
endpoints in Parkinson’s disease, including incontinence, rapid eye
movement sleep disorders, anxiety, and dyskinesia (the impairment
of voluntary movement), which are all debilitating symptoms
associated with the disease.
On March 1, the company announced a joint
development and services agreement with The Parkinson’s Institute
and Clinical Center of Sunnyvale, California. The company will work
with the institute to identify new clinical end points for
Parkinson’s disease and movement disorders that could be used to
determine if natural products can help manage symptoms. The
institute will assist the company in designing trials and creating
protocols using its products.
The company recently announced the
appointment of Parkinson’s Institute CEO Dr. Carrolee Barlow MD,
PhD as an advisor. Dr. Barlow will help to develop solutions and
treatments for Parkinson’s disease utilizing cannabis affiliated
therapies. “We feel very fortunate to collaborate with IGC in a
rigorous research approach to determine whether holistic cannabis
products can alleviate the symptoms of Parkinson’s and movement
disorders,” said Dr. Barlow in a press release announcing the
partnership. “This is an opportunity for the Parkinson’s Institute
and Clinical Center to participate in this scientific study to help
Parkinson’s patients worldwide.”
The Parkinson’s Institute and Clinical Center is
the nation’s only institute that provides patient care, basic
science research, and clinical research in an integrated model.
Patients have come from 38 states and many countries to receive
care, while the experienced team has managed more than 135 clinical
trials and evaluated more than 95 different drugs and
therapies.
Looking Ahead
India Globalization Capital Inc. (NYSE American:
IGC) represents a compelling investment opportunity in the cannabis
industry. With a new partnership in place, the company is well
positioned to advance its Parkinson’s disease therapeutics through
trials and potentially open the door to nearer-term revenue from
health and wellness sales. Investors may want to take a closer look
at the stock given these potential catalysts ahead.
For more information, visit the company’s websites
at www.igcinc.us; http://igcpharma.com ; http://hyalolex.com Follow
us on Twitter @IGCIR and Facebook.com/IGCIR/
Please follow the link to read the full
article:
http://www.cannabisfn.com/igc-partners-advance-cannabinoid-based-parkinsons-disease-therapy-research/
For more information, visit the company’s website
at www.igcinc.us.
About CFN Media
CFN Media (CannabisFN) is the leading creative
agency and media network dedicated to legal cannabis. We help
marijuana businesses attract investors, customers (B2B, B2C),
capital, and media visibility. Private and public marijuana
companies and brands in the US and Canada rely on CFN Media to grow
and succeed.
Learn how to become a CFN Media client company,
brand or
entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access
the world of cannabis from the palm of your
hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number
under the Apple App Store logo to receive a download link text on
your iPhone: http://www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial
investment advisor or broker-dealer. You should always consult with
your own independent legal, tax, and/or investment professionals
before making any investment decisions. The information provided
on http://www.cannabisfn.com (the ‘Site’) is either
original financial news or paid advertisements drafted by our
in-house team or provided by an affiliate. CannabisFN.com, a
financial news media and marketing firm enters into media buys or
service agreements with the companies that are the subject of the
articles posted on the Site or other editorials for advertising
such companies. We are not an independent news media
provider. We make no warranty or representation about the
information including its completeness, accuracy, truthfulness or
reliability and we disclaim, expressly and implicitly, all
warranties of any kind, including whether the Information is
complete, accurate, truthful, or reliable. As such, your use of the
information is at your own risk. Nor do we undertake any obligation
to update the items posted. CannabisFN.com received compensation
for producing and presenting high quality and sophisticated content
on CannabisFN.com along with financial and corporate news.
The above article is sponsored content. Emerging
Growth LLC, which owns CannabisFN.com and CFN Media, has been hired
to create awareness. Please follow the link below to view our full
disclosure outlining our
compensation: http://www.cannabisfn.com/legal-disclaimer/
Contact:
Frank Lane
206-369-7050
flane@cannabisfn.com